Core Insights - Bayer AG's subsidiary BlueRock Therapeutics announced positive 36-month data for bemdaneprocel, a cell therapy for Parkinson's disease [1][8] - The therapy has shown a consistent safety profile and is well tolerated by patients [2][8] - The high-dose cohort demonstrated a significant reduction in motor symptoms, indicating clinically meaningful progress [4][8] Clinical Data - Bemdaneprocel continues to show a favorable safety profile at 36 months, with no adverse events reported [2] - F-Dopa imaging indicates that transplanted cells survive and engraft in the brain after immunosuppression therapy is discontinued [3] - In the high-dose cohort, a mean reduction of 17.9 points in motor symptoms was observed, compared to a 13.5-point reduction in the low-dose cohort [4] Regulatory Progress - Bemdaneprocel received Fast Track Designation from the FDA in 2021 and Regenerative Medicine Advanced Therapy designation in 2024 [5] - A phase III study is currently enrolling participants to assess the therapy's efficacy and safety compared to sham surgery [5] Pipeline Expansion - Bayer has expanded its pipeline in cell and gene therapy through acquisitions, including BlueRock and AskBio [6] - The company is developing therapies for various diseases, including retinal disorders and congestive heart failure [6] Market Performance - Bayer's shares have increased by over 64% year-to-date, contrasting with a 10% decline in the industry [7] - New products like Nubeqa and Kerendia are contributing positively to the pharmaceutical division, offsetting declines in Xarelto sales [9][10]